The production facility will be co-located with the pharmaceutical production site based in Tuas, Singapore.
Novartis CEO Joseph Jimenez said, "We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labor as well as proximity to growth markets in Asia."
The Singapore plant will produce both clinical and commercial monoclonal antibodies to help patients with diseases in autoimmune, respiratory and oncology indications.
The proposed facility is expected to be fully operational by the end of 2016.